Pressed by insurance companies, some drug makers are beginning to adjust what they charge for their drugs based on how well the medicines improve patients' health. Such pay-for-performance contracts started to take hold a few years ago in countries with national health systems, in which the government could effectively block a drug from being used if it was too costly. Some experts hail such arrangements as a welcome step toward healthcare that rewards good outcomes for patients.